Last reviewed · How we verify
Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease
Approved treatments
- Chronic- PF-06480605 50 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease treatment landscape brief
- Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease treatment updates RSS
Frequently asked questions about Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease
What drugs treat Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease?
Tracked treatments include Chronic- PF-06480605 50 mg SC Q4W.
What is the treatment for Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease?
Standard treatment for Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease includes Chronic- PF-06480605 50 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease patent cliff · Moderate to severe non-radiographic axial spondyloarthritis and Crohn's disease CI report
- Treatment: Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing